eprintid: 10109467 rev_number: 17 eprint_status: archive userid: 608 dir: disk0/10/10/94/67 datestamp: 2020-09-09 16:31:37 lastmod: 2021-09-17 22:22:46 status_changed: 2020-09-09 16:31:37 type: article metadata_visibility: show creators_name: Benussi, A creators_name: Ashton, NJ creators_name: Karikari, TK creators_name: Gazzina, S creators_name: Premi, E creators_name: Benussi, L creators_name: Ghidoni, R creators_name: Rodriguez, JL creators_name: Emeršič, A creators_name: Binetti, G creators_name: Fostinelli, S creators_name: Giunta, M creators_name: Gasparotti, R creators_name: Zetterberg, H creators_name: Blennow, K creators_name: Borroni, B title: Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration ispublished: inpress divisions: UCL divisions: B02 divisions: C07 divisions: D07 divisions: F86 keywords: Biomarker, frontotemporal dementia, glial fibrillary acidic protein, magnetic resonance imaging, serum, survival, transcranial magnetic stimulation note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. abstract: BACKGROUND: It is still unknown if serum glial fibrillary acidic protein (GFAP) is a useful marker in frontotemporal lobar degeneration (FTLD). OBJECTIVE: To assess the diagnostic and prognostic value of serum GFAP in a large cohort of patients with FTLD. METHODS: In this retrospective study, performed on 406 participants, we measured serum GFAP concentration with an ultrasensitive Single molecule array (Simoa) method in patients with FTLD, Alzheimer's disease (AD), and in cognitively unimpaired elderly controls. We assessed the role of GFAP as marker of disease severity by analyzing the correlation with clinical variables, neurophysiological data, and cross-sectional brain imaging. Moreover, we evaluated the role of serum GFAP as a prognostic marker of disease survival. RESULTS: We observed significantly higher levels of serum GFAP in patients with FTLD syndromes, except progressive supranuclear palsy, compared with healthy controls, but not compared with AD patients. In FTLD, serum GFAP levels correlated with measures of cognitive dysfunction and disease severity, and were associated with indirect measures of GABAergic deficit. Serum GFAP concentration was not a significant predictor of survival. CONCLUSION: Serum GFAP is increased in FTLD, correlates with cognition and GABAergic deficits, and thus shows promise as a biomarker of disease severity in FTLD. date: 2020-08-14 date_type: published official_url: https://doi.org/10.3233/JAD-200608 oa_status: green full_text_type: other language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1808897 doi: 10.3233/JAD-200608 pii: JAD200608 lyricists_name: Zetterberg, Henrik lyricists_id: HZETT94 actors_name: Zetterberg, Henrik actors_name: Harriot, Anne-Marie actors_id: HZETT94 actors_id: AHARA72 actors_role: owner actors_role: impersonator full_text_status: public publication: Journal of Alzheimer's Disease event_location: Netherlands citation: Benussi, A; Ashton, NJ; Karikari, TK; Gazzina, S; Premi, E; Benussi, L; Ghidoni, R; ... Borroni, B; + view all <#> Benussi, A; Ashton, NJ; Karikari, TK; Gazzina, S; Premi, E; Benussi, L; Ghidoni, R; Rodriguez, JL; Emeršič, A; Binetti, G; Fostinelli, S; Giunta, M; Gasparotti, R; Zetterberg, H; Blennow, K; Borroni, B; - view fewer <#> (2020) Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease 10.3233/JAD-200608 <https://doi.org/10.3233/JAD-200608>. (In press). Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10109467/3/Zetterberg_Serum%20Glial%20Fibrillary%20Acidic%20Protein%20%28GFAP%29%20Is%20a%20Marker%20of%20Disease%20Severity%20in%20Frontotemporal%20Lobar%20Degeneration_AAM.pdf